Clinical trials: Movement Abnormalities
Parkinson's Disease
Extended Long-Term Safety Study of KW-6500
This is a extended long-term safety study in Parkinson's disease patients who have motor response complications on levodopa therapy and completed 12 weeks administrations of KW-6500 in 6500-004 study.
- Trial name
- 6500-005 (NCT01063621)
- Testing
- KW-6500
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Dementia With Lewy Bodies (DLB)
A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)
The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with Dementia with Lewy Bodies (DLB).
- Trial name
- NCT00543855
- Testing
- 3 mg Donepezil hydrochloride, 5 mg Donepezil hydrochloride, 10 mg Donepezil hydrochloride
- Where
- 43 sites in Japan
- Volunteers
- 167 people
- Sponsor
- Eisai Co., Ltd.
Tourette Syndrome
A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome
This study evaluates the efficacy and safety of THX-110 in the management of tics and other symptoms (e.g. rage attacks, anxiety, depression, sleep difficulties) in patients with Tourette syndrome.
- Trial name
- NCT03651726
- Testing
- THX-110 (dronabinol plus PEA)
- Where
- 2 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Neurothera Labs Inc.
Essential Tremor
A Clinical Trial of PRAX-944 in Participants With Essential Tremor
This is a 2-part clinical trial to evaluate the efficacy, safety, and tolerability of 40 and 120 mg oral PRAX-944 compared to placebo in the treatment of adults with essential tremor.
- Trial name
- NCT05021978
- Testing
- Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Praxis Precision Medicines
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Essential Tremor
Upper Limb Tremor Reduction in Essential Tremor Patients
This study is designed to demonstrate the safety, tolerability, and efficacy of the Encora Therapeutics Tremor Mitigation Device in subjects with upper limb tremor caused by Essential Tremor.
- Trial name
- ULTRE (NCT06343285)
- Testing
- Encora Therapeutics Tremor Reduction Device
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Encora, Inc.
Idiopathic Parkinson's Disease
Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease
The objective of this study is to compare the pharmacokinetics and pharmacodynamics of IPX054, carbidopa-levodopa immediate-release tablets, and carbidopa-levodopa controlled-release tablets in subjects with idiopathic…
- Trial name
- NCT00279825
- Testing
- IPX054 200 mg, IPX054 250 mg, CD-LD IR
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Impax Laboratories, LLC
Dyskinesia, Drug-Induced, Parkinson Disease
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
This will be a prospective, multi-center, randomized, double-blind, parallel group, placebo-controlled study, in participants with PD who are on a stable regimen of dopaminergic medication and have at least mild levodopa-induced…
- Trial name
- NCT03987750
- Testing
- Safinamide Methanesulfonate 150mg, Safinamide Methanesulfonate 100mg
- Sponsor
- Zambon SpA
Parkinson Disease
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
- Trial name
- NCT02687542
- Testing
- PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD)
- Where
- 57 sites in United States, Canada and 4 more
- Volunteers
- 108 people
- Sponsor
- Pfizer
Parkinson Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease
This is a Phase I/II randomized, double-blind, placebo-controlled, multiple rising dose study in patients with stable idiopathic Parkinson's disease (PD) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics…
- Trial name
- NCT03257046
- Testing
- ITI-214
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Parkinson Disease
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.
- Trial name
- NCT03877510
- Testing
- IPX203
- Where
- 98 sites in United States, Czechia and 6 more
- Volunteers
- 419 people
- Sponsor
- Impax Laboratories, LLC
Parkinson Disease
Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease
The objectives of this study are to investigate issues or questions about MIRAPEX Tablets as shown below through the Post Marketing Surveillance (PMS) study upon approval.
- Trial name
- NCT02248168
- Testing
- Pramipexole
- Volunteers
- 1,449 people
- Sponsor
- Boehringer Ingelheim
Essential Tremor
A Study to Evaluate the Effectiveness and Safety of ExAblate MRgFUS on Essential Tremor
A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects The objective of this prospective, single-arm study is to test the efficacy…
- Trial name
- NCT03253991
- Testing
- MRgFUS treatment
- Where
- 11 sites in China, Japan and 1 more
- Volunteers
- 154 people
- Sponsor
- InSightec
Parkinson's Disease
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers
The primary study objective is to establish the safety and tolerability of MT101-5 after a single and multiple dose administrations in healthy volunteers.
- Trial name
- NCT05844787
- Testing
- MT101-5
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mthera Pharma Co., Ltd.
Parkinson's Disease (PD)
Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients
The purpose of this study is to determine the effect of two different multiple-dose regimens of nebicapone in comparison to placebo and entacapone 200 mg on the pharmacokinetics of levodopa in Parkinson's Disease (PD) patients.
- Trial name
- NCT02834507
- Testing
- BIA 3-202, Comtan®, Sinemet®
- Volunteers
- 19 people
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease
The objective of this study was to investigate the efficacy and safety of Pramipexole Tablets in patients with Parkinson's disease (who can be treated with L-DOPA concomitantly) in a single blind, comparative method using…
- Trial name
- NCT00240409
- Testing
- Pramipexole, Bromocriptine
- Where
- 7 sites in China
- Volunteers
- 208 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease, Essential Tremor
[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
Clinical study to demonstrate an at least equivalent performance of a new PET molecular Imaging radiopharmaceutical named [18F] LBT-999 in brain imaging compared to the SPECT reference method named [123I]-FP-CIT to establish the…
- Trial name
- NCT04265209
- Testing
- SPECT, PET
- Where
- 16 sites in France
- Volunteers
- 152 people
- Sponsor
- GE Healthcare
Parkinson Disease
Effect of BIA 9-1067 on Rasagiline Pharmacokinetics
The purpose of this study is to investigate the effect of BIA 9-1067 on rasagiline pharmacokinetics in healthy subjects.
- Trial name
- NCT01532128
- Testing
- rasagiline, BIA 9-1067
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Tardive Dyskinesia
Addressing Involuntary Movements in Tardive Dyskinesia
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
- Trial name
- AIM-TD (NCT02291861)
- Testing
- SD-809
- Where
- 106 sites in United States, Czechia and 4 more
- Volunteers
- 298 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Parkinson Disease
A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
When a patient with Parkinson's disease (PD) is initially treated with L-dopa or dopamine agonists, the symptoms of PD improve or disappear.
- Trial name
- NCT01155466
- Testing
- Preladenant 2 mg tablet, Preladenant 5 mg tablet, Preladenant 10 mg tablet
- Volunteers
- 778 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.